GeneDx Presents New Data At The American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels For Patients With Epilepsy
Portfolio Pulse from Benzinga Newsdesk
GeneDx (NASDAQ:WGS) announced new data supporting exome sequencing over multi-gene panels for epilepsy diagnosis, to be presented at the AES annual meeting. The study of 22,500 individuals showed a 25% diagnosis rate with exome sequencing, higher than the 19% with multi-gene panels. 78% of those diagnosed had prior testing, indicating exome sequencing's superior diagnostic ability. Over half of seizure-related genes are not on many epilepsy panels. 11% of positive diagnoses from exome sequencing involved treatment-related genes. GeneDx will also present data on better insurance coverage for exome sequencing. The NSGC and AES recommend exome sequencing as a first-tier test for unexplained epilepsy. GeneDx will host a symposium at the conference discussing the benefits of exome sequencing for epilepsy patients.
December 01, 2023 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GeneDx's new data on exome sequencing for epilepsy diagnosis and its better insurance coverage could position the company as a preferred provider for genetic testing, potentially increasing demand for their services.
The positive data presented by GeneDx on exome sequencing's diagnostic rate and insurance coverage is likely to be viewed favorably by healthcare providers and patients, leading to increased use of their services. This could result in higher revenues for the company in the short term. The endorsement by NSGC and AES further strengthens the case for exome sequencing, potentially leading to broader adoption and preference for GeneDx's services.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100